تداخلات ليراغلوتيد

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (نشرة ليراغلوتيد، تحذير مؤطر)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (نشرة ليراغلوتيد، تحذير مؤطر)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (نشرة سيبروفلوكساسين، التداخلات الدوائية)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (نشرة غليبيزيد وميتفورمين، موانع الاستعمال)

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (نشرة فلوكونازول، التداخلات الدوائية)

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (نشرة كلوروكين، التحذيرات)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (نشرة ليراغلوتيد، تحذير مؤطر)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (نشرة ليراغلوتيد، تحذير مؤطر)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (نشرة ليراغلوتيد، تحذير مؤطر)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (نشرة ليراغلوتيد، تحذير مؤطر)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (نشرة هيدروكسي كلوروكين، التحذيرات والاحتياطات)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (نشرة أبيراتيرون، التحذيرات والاحتياطات)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (نشرة أتازانافير، التحذيرات والاحتياطات)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (نشرة إربيسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (نشرة أسبرين وديبيريدامول، التداخلات الدوائية)

Consideration should be taken in patients being treated with antidiabetic agents. (نشرة أسيتازولاميد، التداخلات الدوائية)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (نشرة أسيتريتين، التداخلات الدوائية)

Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions (6.2) ] . (نشرة إكسيناتيد، التحذيرات والاحتياطات)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (نشرة أملوديبين وبينازيبريل، التداخلات الدوائية)

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. (نشرة إنالابريل وهيدروكلوروثيازيد، الاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (نشرة أورليستات، التحذيرات والاحتياطات)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (نشرة أوفلوكساسين، التحذيرات)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (نشرة أوكتريوتيد، التحذيرات والاحتياطات)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (نشرة أولميسارتان وأملوديبين وهيدروكلوروثيازيد، التداخلات الدوائية)

• Antidiabetic drugs: Dosage adjustment may be required. (نشرة أولميسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (نشرة إيتراكونازول، التداخلات الدوائية)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (نشرة بريدنيزولون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (نشرة بريغابالين، التحذيرات والاحتياطات)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (نشرة بريمونيدين وتيمولول، التحذيرات والاحتياطات)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (نشرة بوتالبيتال وأسبرين وكافيين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (نشرة بيسوبرولول، التحذيرات)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (نشرة بيسوبرولول وهيدروكلوروثيازيد، الاحتياطات)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (نشرة بيكساغليفلوزين، التداخلات الدوائية)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (نشرة بينازيبريل، التداخلات الدوائية)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (نشرة بينازيبريل وهيدروكلوروثيازيد، التداخلات الدوائية)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (نشرة بيندولول، التحذيرات)

Congestive Heart Failure ACTOS, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when ACTOS is used in combination with insulin. (نشرة بيوغليتازون، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (نشرة تراندولابريل، التداخلات الدوائية)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (نشرة ترانيلسيبرومين، التحذيرات والاحتياطات)

Dyrenium (triamterene) may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (نشرة تريامتيرين، التداخلات الدوائية)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (نشرة تريامتيرين وهيدروكلوروثيازيد، التداخلات الدوائية)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (نشرة تريامسينولون، التداخلات الدوائية)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (نشرة تيلميسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (نشرة تيمولول، التحذيرات والاحتياطات)

…Coadministered Drug (Dose Regimen) * Dapagliflozin (Dose Regimen) * Effect on Dapagliflozin Exposure [% Change (90% CI)] C max AUC † No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10… (نشرة داباغليفلوزين، التداخلات الدوائية)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (نشرة دارونافير، التحذيرات والاحتياطات)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (نشرة دارونافير وكوبيسيستات، التحذيرات والاحتياطات)

Caution should be exercised when used with antidiabetic drugs. (نشرة دانازول، التداخلات الدوائية)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (نشرة دورزولاميد وتيمولول، التحذيرات والاحتياطات)

Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY. (نشرة دولاغلوتيد، التحذيرات والاحتياطات)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (نشرة ديكساميثازون، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (نشرة ريتونافير، التحذيرات والاحتياطات)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (نشرة ريفابنتين، التداخلات الدوائية)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (نشرة ريفامبيسين، التداخلات الدوائية)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (نشرة سالسالات، التداخلات الدوائية)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (نشرة سبيرونولاكتون وهيدروكلوروثيازيد، التداخلات الدوائية)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (نشرة سوتالول، التداخلات الدوائية)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (نشرة سوماتروبين، التحذيرات والاحتياطات)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (نشرة سونيتينيب، التحذيرات والاحتياطات)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with RYBELSUS or OZEMPIC tablets. (نشرة سيماغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (نشرة فالسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (نشرة فلودروكورتيزون، التداخلات الدوائية)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (نشرة فلوكسيتين، التحذيرات والاحتياطات)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (نشرة فوريكونازول، التداخلات الدوائية)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (نشرة فوسامبرينافير، التحذيرات والاحتياطات)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (نشرة فينترمين، التحذيرات والاحتياطات)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (نشرة كابيسيتابين، التداخلات الدوائية)

Insulin and oral hypoglycemics action may be enhanced. (نشرة كارفيديلول، التداخلات الدوائية)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (نشرة كاناغليفلوزين، التداخلات الدوائية)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (نشرة كانديسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (نشرة كلاريثرومايسين، التحذيرات والاحتياطات)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (نشرة كلوروثيازيد، التداخلات الدوائية)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (نشرة كيتوكونازول، التداخلات الدوائية)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (نشرة لانريوتيد، التحذيرات والاحتياطات)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (نشرة لوبينافير وريتونافير، التحذيرات والاحتياطات)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (نشرة لوسارتان وهيدروكلوروثيازيد، التداخلات الدوائية)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (نشرة ليزينوبريل، التداخلات الدوائية)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (نشرة ليزينوبريل وهيدروكلوروثيازيد، التداخلات الدوائية)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (نشرة ليفوفلوكساسين، التحذيرات والاحتياطات)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Antidiabetic agents Carefully monitor blood glucose. (نشرة موكسيفلوكساسين، التداخلات الدوائية)

In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide regardless of insulin and/or metformin use. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Antidiabetic drugs: Dosage adjustment may be required. (نشرة ميتوبرولول وهيدروكلوروثيازيد، التداخلات الدوائية)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (نشرة ميتولازون، التداخلات الدوائية)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (نشرة ميثيل بريدنيزولون، التداخلات الدوائية)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (نشرة ليراغلوتيد، التحذيرات والاحتياطات)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (نشرة نادولول، التحذيرات)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (نشرة نالتريكسون وبوبروبيون، التحذيرات والاحتياطات)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (نشرة هيدروكلوروثيازيد، التداخلات الدوائية)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (نشرة هيدروكورتيزون، التداخلات الدوائية)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (نشرة بوبروبيون، التحذيرات والاحتياطات)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (نشرة تولميتين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Antidiabetic drug requirements (i.e., insulin) may be altered. (نشرة ديثيل بروبيون، التداخلات الدوائية)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (نشرة سلفاديازين، التداخلات الدوائية)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (نشرة فينديميترازين، التداخلات الدوائية)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (نشرة كلوزابين، التحذيرات والاحتياطات)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (نشرة لوفاستاتين، التداخلات الدوائية)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (نشرة موكسيبريل، التداخلات الدوائية)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (نشرة ميكونازول، التداخلات الدوائية)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (نشرة نيفيديبين، الاحتياطات)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (نشرة سولينداك، التداخلات الدوائية)